Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs
Description	CD19 molecule

Gene symbol	CD22	Synonyms	SIGLEC-2, SIGLEC2	Type of gene	protein-coding
Chromosome	19	Map location	19q13.12	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	CD22 molecule

GTO ID	GTC0388
Trial ID	NCT03287817
Disease	Diffuse Large B-Cell Lymphoma
Altered gene	CD19\|CD22
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	AUTO3
Generation	3rd
Phase	Phase1\|Phase2
Recruitment status	Active, Not Recruiting
Title	CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Year	2015
Country	United States
Company sponsor	Autolus Limited
Other ID(s)	AUTO3-DB1\|2016-004682-11

Vector information

Vector	retrovirus
Construct	scFv-OX40-4-1BB-CD3ζ
Transgene/Inserted gene	both an anti-CD19 (OX40 co-stim) and an anti-CD22 (41BB co-stim) CAR

Clinical Result

Cohort 1

Administration route	intravenous infusion
Dosage	50E6 cells, 150E6 cells, 450E6 cells
Donor type	Autologous
Pts	19
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	Among the 11 treated at dose > 50E6, the ORR and CRR were 64% and 55%, and all CRs are ongoing (1-12 mth).
Adverse reactions	Grade > 3 AEs:neutropenia(89%), thrombocytopenia(58%), anemia(47%), febrile neutropenia(16%), hypophosphataemia(16%)
References	DOI: 10.1200/JCO.2020.38.15_suppl.8001

Relationship Graph

Overview of Knowledge Graph